Shares of Biocon Ltd were trading in the green and 1% higher on 27 November after the company announced that the US Food and Drug Administration had designated its Bengaluru drug substance facility as a VAI. The acronym VAI stands for Voluntary Action Indicated.

The FDA visited the property from 26 August to 3 September 2025. The facility manufactures and supplies rh-Insulin and the biosimilar medicinal ingredient Pegfilgrastim to the United States. The term “rh-Insulin” refers to human recombinant insulin.

In an exchange filing, Biocon Biologics stated that the company remained committed to worldwide quality and compliance standards.

Meanwhile, Biocon is considering combining Biocon Biologics with the parent company, according to sources. The proposed transaction, which may value the company at around $4.5 billion, represents a departure from an earlier proposal to float the biologics unit.

The company is understood to be in advanced talks with minority owners about a potential share swap, and it has also considered a cash plus swap structure.

Chairperson Kiran Mazumdar Shaw said that the group is considering a variety of options, including an IPO, merger, or share swap, and has hired Morgan Stanley to determine the optimum value creation strategy.

At 12:28 pm, the shares of Biocon were trading 0.063% lower at Rs 398.20 on NSE.

Tired of guessing stocks to trade in daily?
Unicorn Signals empowers you with powerful tools like daily stock scans for Intraday, Swing & Investing, Market Predictions and much more. Download the Unicorn Signals app today and take control of your investments!